Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05859997 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

StatusEnrolling by Invitation
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Enrolling by Invitation
    • Primary completion date changed from estimate of Jul 17, 2024 to May 27, 2024
    • Study completion date: Jul 17, 2025 to May 27, 2025
    • Site details revised
    v5
  2. Primary endpoint revised
    • Secondary endpoints revised (2)
    v4
  3. Primary endpoint revised
    • Eligibility criteria shortened, about 30 words
    • Secondary endpoints revised (2)
    v3
  4. Start date: Apr 17, 2023 to May 17, 2023
    • Eligibility criteria shortened, about 1 word
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bioray Laboratories
10 trials monitored
See 1 trial at risk
Lupus (SLE)
666 trials monitored
See 25 trials at risk
Scleroderma
324 trials monitored
See 13 trials at risk
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
Trial Details
NCT Number NCT05859997
Lead Sponsor Bioray Laboratories
Collaborators: Shanghai Changzheng Hospital
Conditions
(from sponsor)		 Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Systemic Vasculitis, Antiphospholipid Syndrome
Related terms Antiphospholipid Syndrome, Lupus Erythematosus, Systemic, Myositis, Scleroderma, Systemic, Sjogren's Syndrome
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov